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Diabetes mellitus, a metabolic disorder rapidly spreading worldwide affects multiple organs and body functions. Stevia 
rebaudiana (Bertoni), belonging to the Asteraceae family is a herb with medicinal and commercial importance to cure 
chronic diseases like diabetes mellitus. The present study was aimed to explore the antidiabetic effect of two reference 
standards like Steviol Glycosides System Suitability (SGSS, a mixture of nine steviol glycosides) and Rebaudioside A in 
alloxan-induced diabetic rats. In this regard,  diabetes was induced in rats by administration of a single intraperitoneal (i.p.) 
injection of alloxan monohydrate (150 mg/kg body weight). After exposure to alloxan monohydrate, the overall intracellular 
antioxidant functions get disturbed which significantly increase the blood glucose levels, plasma malondialdehyde and sialic 
acid content. The oral administration of SGSS and Reb A at a dose of (20 and 30 mg/kg b.wt.) for a period of 21 days to 
diabetic rats significantly (P ˂0.05) reduced the blood glucose levels when compared with alloxan-induced diabetic control 
(DC) rats of group II and restore the antioxidant potential by decreasing the oxidative damage and also normalizes
hyperlipidemic indices. The study demonstrated that bioactive components (steviol glycosides) of S. rebaudiana have
potential therapeutic prospects to attenuate diabetes and its related complications.
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Introduction 
Diabetes mellitus is a group of metabolic disorder 
mainly identified as long term hyperglycemia due to 
insufficient action or secretion of insulin in the body1. 
Long term increase in levels of blood glucose is 
associated with major complications leading to 
neuropathy, retinopathy, cardiomyopathy, and 
nephropathy. Simultaneously, many other factors play a 
major role in the pathogenesis of diabetes by damaging 
beta cells and decreasing insulin secretion2.  In diabetes, 
there is an increased generation of free radicals 
or reactive oxygen species (ROS) due to glucose 
autoxidation, increased polyol (sorbitol) pathway, 
non-enzymatic glycation of proteins, hyperglycemia, 
decreased antioxidant defences and lipid peroxidation 
leading to damage of enzymes, cellular mechanisms and 
modulation in insulin signalling due to oxidative stress3.   
Plant-derived bioactive compounds or natural 
antioxidants are efficient to reduce the free radicals 
formation and thus prevent oxidative damage 
effectively4. Traditional practices are the best option 
for the treatment of diabetes when compared with 
synthetic ones as many plants with their natural 
bioactive components initiate less toxicity more 
efficiently and cost-effectively with a low incidence 
of side effects. The natural bioactive compounds 
show their efficacy through different mechanisms 
which help in the reduction of high blood glucose 
levels. The few promising mechanisms are an 
increase in regeneration of β-cell mass, enhancing 
insulin’s activity and inhibiting insulinase activity5. 
Therefore, in recent years there is an urgent need to 
investigate naturally originated plant-derived anti-
diabetic and antioxidative agents with the vast reserve 
of phytochemicals.  
Stevia rebaudiana (Bertoni), belonging to the 
family Asteraceae is a worldwide recognized herb 
with medicinal and commercial importance mainly 
approved as a low-calorie natural sweetener. Natural 
bioactive compounds like phenols, flavonoids, 
alkaloids, sugars, glycosides, and essential oils are 
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which repairs the body systems and enhances the 
endogenous antioxidant levels. Approximately thirty 
ent-kaurene diterpene glycosides have been isolated 
from leaves of different species of Stevia plants 
generally recognized as steviol glycosides - 
stevioside, rebaudiosides A – E, dulcoside A, 
steviolbioside etc. The aglycone part of such 
glycosides is steviol (ent-13-hydroxy kaur-16-en-19-
oic acid) which is involved in constructing a C19-
ester linkage between the glucose unit and a C19-
carboxylic function, together with the formation of 
ether linkages using combinations of glucose, xylose 
and rhamnose moieties with C13-hydroxy group6.  
The glycoside of major interest because of its 
sweetening property is Rebaudioside A (4α)-13-[(2-
O-β-D-glucopyranosyl-3-O-β-Dglucopyranosyl-β-D-
glucopyranosyl)-oxy] kaur-6-en-8 oic acid β-D-
glucopyranosyl ester). It is a glucosylated steviol
glycoside found in large quantities and an active
noncaloric, non-toxic and non-glycemic natural
sweetener, extracted and purified from S. rebaudiana,
approximately 1% in dried leaves. It has been
reported that these different steviol glycosides and
majorly Rebaudioside A possess additional
functionalities by maintaining and regulating different
metabolic processes in the body with possible
beneficial effects on health including antioxidant,
antimicrobial, anti-diabetic, antihypertension and
cardio-protective activities7. Earlier studies 
established the protective effect of Rebaudioside A by
stimulating the secretion of insulin from pancreatic
β-cells and thus decreasing the condition of
hyperglycemia due to its antioxidant property through
scavenging ROS8.
There is only a little information available 
regarding the biological actions of Rebaudioside A in 
reducing the complications of diabetes in rat model7. 
Additionally, more evidence is required on the 
antidiabetic activity of a mixture of steviol glycosides 
and individual glycoside Rebaudioside A for their 
various biological actions that reduce diabetic 
complications directly or indirectly in alloxan-induced 
diabetic rats. The Joint Food and Agriculture 
Organization (FAO/WHO) Expert Committee on 
Food Additives (JECFA) purposely requested for 
additional studies to be performed involving repeated 
exposure to dietary and therapeutic doses of steviol 
glycosides in people with diabetes to help describe an 
acceptable dietary intake (ADI) of steviol glycosides9. 
In the United States and Europe, the first Stevia-based 
sweeteners were widely used. In a variety of food 
products, mixtures of different glycosides including 
Rebaudioside A are now being regularly used.  
To date, there have been no research articles 
reported on the antidiabetic and protective effect of 
standard compounds Steviol Glycosides System 
Suitability (SGSS, a mixture of nine steviol 
glycosides) and individual glycoside components like 
Rebaudioside A (Reb A) in alloxan-induced diabetic 
rats. It was aimed to study whether the mixture of 
steviol glycosides/SGSS or individual glycoside Reb 
A possesses a similar property to reduce tissue 
complications by increasing insulin secretion from 
beta cells which helps in maintaining blood glucose 
homeostasis7. To better understand the complexity of 
the disease, the blood glucose, body weight and other 
biochemical parameters are integrated to find the 
overall effect of the mixture of nine steviol glycosides 
and individual Reb A, which was compared with the 
effect of standard drug insulin.  
Materials and Methods 
Chemicals 
Analytical grade reagents were used to perform the 
experiments. Alloxan monohydrate (2,4,4,6- tetra- 
oxohexahydropyrimidine) was procured from Loba 
Chemie, Mumbai, India. Insulin was purchased from 
SRL chemicals. N-Acetylneuraminic acid (NANA) 
and resorcinol were purchased from Sigma Aldrich, 
India. ERBA Mannheim (Transasia Bio Medicals 
Ltd., Daman, India) kits were purchased for the 
estimation of biochemical parameters. 
Test Supplements 
Two reference standards SGSS, (a mixture of nine 
steviol glycosides i.e., stevioside, rebaudioside A-F, 
dulcoside A, rubusoside and steviolbioside and 
RebaudiosideA (Reb A) were purchased from Sigma-
Aldrich, St. Louis, MO, USA. 
Animals and Diets 
Healthy Wistar albino rats of both sexes (4-5 
months old, weighing 150-200 g) were used for the 
study. Before the initiation of the experiment, all the 
rats were acclimatized for one week to the new 
standard laboratory conditions. They were housed 
under a controlled facility (25±5 °C) with a 12 h light/ 
12 h dark cycle, fed with nutrient-rich diet pellets and 
water ad libitum. Safe handling and treatment of all 
the rats were done according to the principles of the 
institutional animal ethics committee constituted 
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under the directions of the committee for the purpose 
of control and supervision of experiments on animals 
(CPCSEA), India. All the experimental protocols 
were approved by the Animal Care and Ethical 
Committee (849/GO/Re/04/CPCSEA) of the 
University of Allahabad. 
Diabetes induction 
The overnight fasted Wistar albino rats were 
injected intraperitoneally (i.p.) with alloxan 
monohydrate (2, 4, 5, 6-tetraoxyprimidine) dissolved 
in 0.9% normal saline at a dose of 150 mg/kg b.wt.10. 
Alloxan administration massively destroys pancreatic 
beta cells which induce toxicity, hyperglycemia and 
insulin-dependent diabetes mellitus (IDDM). The 
alloxan-injected rats were allowed to access 20% 
glucose solution for the next 24 hours to prevent 
initial drug-induced hypoglycemic shock. The 
diabetes was confirmed after one week of alloxan 
injection by measuring the levels of elevated blood 
glucose with the help of a glucometer (Accu-Chek, 
Roche Diagnostics, USA). The rats showing fasting 
blood glucose above (160 mg/dL) were considered 
diabetic and selected for further study.  
Acute toxicity study for determining the dosage 
After one week of diabetes induction, the overnight 
fasted rats were included in the study and body weight 
was recorded just before use. They were randomly 
divided into control and treatment groups, with four 
rats in each group. The control group received vehicle 
only, whereas the treatment groups were orally 
administered with pure compounds (SGSS) and 
individual glycoside (Reb A) ranging from 10 to 
50 mg/kg b.wt. Animals were closely observed for 
any behavioural changes and other physical activities 
and after 5 hrs the blood glucose was determined11. 
The maximum antihyperglycemic effect brought by 
the lowest dose of each compound was given through 
oral intubations for repeated administration. The 
doses selected for the pure compounds (20 and 
30 mg/kg b.w.) were administered every day till the 
completion of the experimental period (i.e., 21 days). 
Experimental protocol 
After inducing diabetes successfully, the 
experimental rats were divided into 7 groups 
containing 6 rats in each group (n=6). Pure 
compounds like (SGSS) and Reb-A were dissolved in 
distilled water which was administered orally to the 
experimental groups using the intragastric tube for 21 
days. Group I: Normal control (NC) receiving no 
treatment (without alloxan or supplementation); 
Group II: Diabetic control (DC) injected with a single 
dose of alloxan monohydrate intraperitoneally10; 
Group III: Diabetic insulin group (DI) injected 
subcutaneously with three units of NPH insulin (NPH 
huminsulin, Lilly Egypt)12 dissolved in distilled water 
were given twice a day; Group IV: Diabetic + SGSS 
(20 mg/kg b.w.); Group V: Diabetic + Reb A 
(20 mg/kg b.w.); Group VI: Diabetic + SGSS 
(30 mg/kg b.w.); and Group VII: Diabetic + Reb A 
(30 mg/kg b.w.). 
Estimation of body weight 
The body weight of the control group and all the 
treated groups were recorded on day 0 (pre-treatment) 
and days 3, 5, 7, 14 and 21 post-treatment. A calibrated 
and standardized electronic balance was used for taking 
the body weight of rats (expressed in g). 
Blood samples collection and estimation of blood glucose 
On day 0 (pre-treatment) and during the treatment 
(day 3, 5, 7, 14 and 21), the blood samples were 
collected from the rats tail vein for estimating blood 
glucose parameters (expressed as mg/dL) using 
glucose test strips of an electronic glucometer (Accu-
Chek, Roche Diagnostics, USA). 
Isolation of plasma and serum 
The rats were sacrificed under the influence of light 
anaesthesia at the end of the experimental period. The 
cardiac was punctured and blood samples were 
collected into heparin rinsed 10 unit/mL of 
anticoagulant syringes (for serum collection, 
anticoagulant was not used) which were transferred 
into the test tubes and then red blood cells (RBCs) 
were pelleted by centrifugation at 800 g for 10-15 
minutes at 4 °C. The separated plasma was stored 
immediately at -80 °C until used for biochemical 
estimations13. The RBCs and 15% of packed red 
blood cells (PRBCs) were washed twice with cold 
phosphate-buffered saline (PBS) (0.9% NaCl and 
10 mmol L−1 Na2HPO4; pH 7.4).  
Determination of erythrocyte malondialdehyde (MDA) 
content 
Erythrocyte MDA was evaluated according to the 
method by Esterbauer and Cheeseman14 with slight 
modification. Packed erythrocytes of 0.2 mL were 
suspended in 3 mL PBS containing 0.5 mM glucose 
(pH 7.4). The suspension of 0.2 mL was added to 
1 mL of 10% trichloroacetic acid and 2 mL of 0.67% 
thiobarbituric acid. The obtained solution was boiled 
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for 20 minutes at 90–100 °C and then cooled. 
Consequently, the mixture was centrifuged at 1000 g 
for 5 minutes and the absorbance of the supernatant 
was read at 532 nm. The MDA concentration in 
erythrocytes was calculated using extinction 
coefficient (ε = 31,500) and expressed as nmol·mL−1 
of packed erythrocytes. 
Determination of membrane and plasma sialic acid (NANA) 
levels 
The sialic acid level was estimated in 
membrane/plasma according to the method given by 
Spyridaki and Siskos15. Periodic acid-schiff (0.041 M) 
of 0.10 mL was added in a test tube containing 
500 μL diluted (20 times) sample solution. The 
solution was thoroughly mixed and allowed to stand 
in an ice bath for 30 min. Afterwards, 1.25 mL of 
resorcinol working solution (5 mL of 6.0% resorcinol 
solution, 0.125 mL of 0.1 M copper sulphate solution 
and 19.875 mL of distilled water along with 50 mL of 
10 M HCl and final volume was raised) was added, 
mixed and heated at 98 °C for 5 minutes. In an ice 
bath, the tubes were allowed to cool for 2 minutes and 
3.25 mL of n-butanol was finally added. The solutions 
were vigorously mixed and the tubes were placed in a 
water bath at 37 C for 3 minutes (for colour 
stabilization). The absorbance was immediately 
measured after removing the solutions from the water 
bath at 625 nm against a reagent blank set at zero. For 
the preparation of the calibration graph, standard 
solutions of NANA in the range of 20–200 μM and 
the unknown concentrations of total sialic acid in 
samples were calculated. A level of sialic acid in the 
membrane is calculated in terms of μg/mg membrane 
protein whereas in plasma sialic acid is measured 
as μM. 
Total antioxidant activity (FRAP) 
Ferric reducing ability of plasma (FRAP) assay 
was performed to study the total antioxidant potential 
of plasma according to the method reported by Benzie 
and Strain16 with slight modification. Working FRAP 
reagent was prepared from 300 mmol/L acetate buffer 
(pH 3.6), 20 mmol/L ferric chloride and 10 mmol/L 
2,4,6-tripyridyl-s-triazine made up in 40 mmol/L 
hydrochloric acid. These solutions were mixed in the 
ratio of 10:1:1 (vol/vol/vol). In 100 μL of plasma, the 
prepared FRAP reagent (3 mL) was mixed thoroughly 
and the absorbance was recorded at 593 nm at 
30s intervals for 4 min. Fe (II) concentration 
(100–1000 μmol/L) in an aqueous solution was used 
for calibration. The regression equation was used for 
calculating the FRAP values (μmol Fe (II)/L) in 
plasma. 
Biochemical estimations 
Standard diagnostic kits were used for estimating 
biochemical parameters (total cholesterol, bilirubin, 
alkaline phosphatase, urea, creatinine, and uric acid) 
from previously isolated heparinised plasma. 
Statistical analysis 
The data obtained were presented as 
mean±standard deviation. One way analysis of 
variance (ANOVA) test was performed by using 
statistical analysis, followed by Bonferroni test using 
graph pad prism software package, version 5.0. 
The values of P ˂0.05 were considered statistically 
significant. 
Results  
Effects on body weight 
In diabetes, one of the major symptoms is weight 
loss which was also noticed in this study. The change 
in body weight was observed in all the groups noted 
on days 0, 3, 5, 7, 14, and 21. The administration of 
the drug alloxan damages the pancreatic beta cells and 
provokes a condition of insulin deficiency which 
accelerates the body weight reduction leading to a 
condition of wasting. Significant (P <0.05) difference 
was observed for the change in body weight in 
alloxan-induced diabetic control (DC) rats when 
compared with (SGSS and Reb A) treated diabetic 
rats (Fig. 1). Stable body weight was observed in the 
normal control (NC) group whereas a significant 
decrease in body weight (155.26, 128.01, 115.67, 
109.12, 98.34, and 85.89 g) on days 0, 3, 5, 7, 14, and 21 
Fig. 1 — Graphical representation of changes in the body weight
(gm) of normal and diabetic rats. 
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days were seen in group II (alloxan-induced negative 
control) rats. Rats of group III (positive control treated 
with standard drug Insulin) showed a significant 
increase in the body weights from 171.01 to 230.22 g. 
Oral administration of SGSS and Reb A (20 mg/kg b.w.) 
to diabetic induced rats in groups IV and V significantly 
increase the body weight (177.23 and 180.01 g) whereas 
groups VI and VII (30 mg/kg) also showed a significant 
increase in body weight (179.31 and 185.12 g) on day 
21 as compared to day 0 value. Post-treatment with 
SGSS and Red A (20 and 30 mg/kg b.w.) significantly 
(P <0.05) increase the body weight in alloxan-induced 
diabetic rats compared with diabetic control rats (DC). 
Effect on blood glucose 
Oral administration of SGSS and Reb A (20 and 
30 mg/kg b.w.) daily for a period of 21 days to 
diabetic rats significantly (P <0.05) decreased the 
level of blood glucose when compared with alloxan-
induced diabetic control (DC) rats of group II 
(Table 1). During the study, period the diabetic rats of 
group III treated with antidiabetic reference drug 
insulin also showed a significant decrease in blood 
glucose levels from day 5 to 21 and maintained it to 
normal standard levels. SGSS and Reb A treated 
(20 mg/kg b.w.) diabetic rats of groups IV and V 
showed normal blood glucose levels (95.11 and 92.13 
mg/dL) on day 21, while diabetic rats of groups VI 
and VII were treated with SGSS and Reb A(30 mg/kg 
b.w.) also exhibit a remarkable decrease in blood
glucose (96.23 and 88.53 mg/dL), close to the value
of day 0. The produced results by the standard
compounds were found to be dose-dependent.
Erythrocyte malondialdehyde (MDA) content 
Plasma malondialdehyde content was significantly 
(P ˂0.05) lower in a normal control group, insulin-
treated group, SGSS and Reb-A treated diabetic group 
compared with the diabetic untreated control group. 
Administration of these pure compounds (20 and 
30 mg/kg/day) significantly reduces the level of 
plasma malondialdehyde (MDA) content in diabetic 
rats of groups IV to VII, similar to insulin. It protects 
the erythrocytes from alloxan-induced hyperglycemia, 
as evidenced by the decreased MDA levels (Fig. 2). 
Plasma sialic acid (NANA) levels 
A significant (P ˂0.05) increase in plasma sialic 
acid content was observed in alloxan treated rats in 
group II as compared to normal control rats in group 
I. Administration with pure compounds SGSS and
Reb-A at a dose of (20 and 30 mg/ kg b.w.) in
alloxan-induced diabetic rats in groups IV to VII,
retains more sialic acid content in plasma when
compared with normal rats in group I. Furthermore,
treatment with insulin also reduces the sialic acid
level in diabetic rats of group III as shown in Fig. 3.
Effect on biochemical parameters 
The results of SGSS and Reb-A at a dose of 
(20 and 30 mg/kg/day) on plasma total cholesterol, 
bilirubin (total and direct), urea, creatinine, uric acid 
and alkaline phosphatase of normal and alloxan-
Table 1 — Effect of Steviol Glycosides System Suitability (SGSS) and Rebaudioside (Reb A) on blood glucose concentration 
Blood glucose concentration (mg/dL) 
Groups Treatments Day 0 Day 3 Day 5 Day 7 Day14 Day 21 
I NC 82.34±4.98 88.12±5.19 86.23±5.14 88.98±4.98 89.01±3.15 85.05±5.15
II DC 97.56±5.14 372.91±6.14 398.99±5.88 409.01±4.72 458.91±4.25 465.32±5.65 
III D+I 86.19±4.99 132.18±5.72 108.51±5.63 101.27±3.98 97.86±5.02 89.01±5.72 
IV D+SG (20 mg) 98.07±5.57 295.28±4.28 221.76±5.89 125.15±3.98 107.15±4.78 95.11±5.61 
V D+Reb-A (20 mg) 85.56±4.28 312.21±5.93 207.43±4.21 109.27±5.62 103.01±3.32 92.13±4.80 
VI D+SG (30 mg) 105.14±4.52 286.67±5.21 216.35±4.86 120.08±5.78 105.21±5.65 93.23±4.91 
VII D+Reb-A (30 mg) 82.14±5.28 323.21±3.93 201.01±5.21 107.36±5.62 101.72±5.32 88.53±5.21 
Each value represents mean±SD, n=6, P <0.05 significant 
Fig. 2 — Levels of malondialdehyde (MDA) content in normal
control and experimental groups. The value represents the
mean±SE for six rats per group.  
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induced diabetic rats after 21 days of treatment are 
presented in Table 2. 
The total cholesterol was found to be significantly 
(P ˂0.05) lower in normal rats (80.92 mg/dL) 
when compared to alloxan-induced diabetic rats 
(99.42 mg/dL). Rats of group III (Insulin treated) 
restore cholesterol level (84.98 mg/dL) close to 
normal. Administration with SGSS and Reb-A at a 
dose of (20 mg/kg) in alloxan-induced rats of IV and 
V resulted in a significant decline in levels of total 
cholesterol (82.40 and 83.85 mg/dL) while rats in 
groups VI and VII (30 mg/kg) also showed a 
significant decrease in total cholesterol (80.15 and 
81.32 mg/dL) as shown in Table 2. 
The direct and total bilirubin levels were shown in 
Table 2. Significantly (P ˂0.05) higher levels of 
bilirubin (direct and total) were observed in alloxan-
induced diabetic rats (0.36 and 3.05 mg/dL) when 
compared with normal control rats of Group I 
(0.25 and 0.76 mg/dL). The rats in group III (insulin-
treated) shows normal parameters for direct and total 
bilirubin (0.26 and 1.71 mg/dL). The oral 
Administration of SGSS and Reb-A at a dose of 
20 mg/kg in alloxan-induced rats of groups IV and V 
resulted in a significant decline in the direct (0.31 and 
0.34 mg/dL) and total bilirubin (1.55 and 1.47 mg/dL) 
whereas rats in groups VI and VII (30 mg/kg) also 
showed a decreased direct (0.28 and 0.31 mg/dL) and 
total bilirubin (1.43 and 1.44 mg/dL). 
Significant (P ˂0.05) increase in the concentration 
of plasma alkaline phosphatase was observed in 
alloxan treated rats in group II (422.19 mg/dL) when 
compared to normal control rats in group I 
(197.65 mg/dL). Decreased level of alkaline 
phosphate was also observed in insulin-treated rats 
(230.51 IU/L). Administration of SGSS and Reb A at 
a dose of 20 mg/kg in alloxan-induced rats of groups 
IV and V offered a significant decline in the level of 
alkaline phosphatase (211.14 and 213.18 IU/L), while 
the dose 30 mg/kg administered to rats in groups VI 
and VII (207.01 and 210.21 IU/L) restored the level 
of alkaline phosphatase close to a normal level as 
shown in Table 2. 
Significantly (P ˂0.05) higher concentration of 
urea (61.50 mg/dL), creatinine (2.50 mg/dL), and uric 
acid (0.99 mg/dL) was observed in alloxan treated rats 
of group II when compared with normal rats in Group 
I for urea (38.52 mg/dL), creatinine (1.33 mg/dL) and 
uric acid (0.58 mg/dL). Insulin treated diabetic rats in 
group III also showed decreased levels of urea 
(41.02 mg/dL), creatinine (0.84 mg/dL) and uric acid 
(0.38 mg/dL). However, administration with SGSS 
and Reb-A at a dose of (20 mg/kg) in alloxan treated 
Fig. 3 — Levels of plasm sialic acid content in normal, control
and experimental groups. The values represent the mean±SE for
six rats per group. 
Table 2 — Effect of ethanolic leaf extracts of S. rebaudiana on biochemical parameters in normal 
and alloxan-induced diabetic rats after 21 days of treatment 
Biochemical assays














Normal Control 80.92±0.79 0.25±0.15 0.76±0.09 197.65±5.97 38.52±2.26 1.33±0.32 0.58±0.09 
Diabetic Control 99.42±3.67 0.36±0.12 3.05±0.62 422.19±7.78 61.50±7.82 2.50±0.19 0.99±0.32 
Diabetic+Insulin 84.98±0.46 0.26±0.05 1.71±0.02 230.51±14.9 41.02±5.11 0.84±0.89 0.38±0.05 
Diabetic+SGSS  
(20 mg/kgb.wt) 
82.40±0.44 0.31±0.34 1.55±0.34 211.14±8.12 36.81±3.10 0.59±0.155 0.64±0.08 
Diabetic +Reb A 
(20 mg/kg b.wt) 
83.85±0.73 0.34±0.06 1.47±0.527 213.18±15.0 35.90±6.34 0.48±0.14 0.61±0.24 
Diabetic+SGSS  
(30 mg/kgb.wt) 
80.15±3.77 0.28±0.13 1.43±1.26 207.01±12.5 36.19±2.10 0.54±0.10 0.59±0.13 
Diabetic+Reb A  
(30 mg/kgb.wt) 
81.32±1.33 0.31±0.29 1.44±0.09 210.21±14.2 34.81±4.63 0.45±0.28 0.57±0.88 
Each value represents mean±SD, n=6, P <0.05 significant 
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rats of groups IV and V significantly reduce the blood 
urea (36.81 and 35.90 mg/dL), creatinine (0.59 and 
0.48) and uric acid (0.64 and 0.61) concentration, 
while administration of (30 mg/kg) to diabetic rats in 
groups VI and VII also showed decreased urea 
(36.19 and 34.81 mg/dL), creatinine (0.54 and 
0.45 mg/dL) and uric acid levels (0.59 and 
0.57 mg/dL) as shown in Table 2. 
Discussion 
Diabetes mellitus is a metabolic disorder majorly 
characterized by hyperglycemia, insulin resistance, 
and several other long term complications. Increased 
oxidative stress, free radicals production, and 
impaired antioxidant defences lead to the 
development and progression of diabetes. For the 
management of diabetes, many drugs are available 
which pose to have drawbacks like restricted 
pharmacokinetic properties, secondary failure rates, 
high costs and serious adverse effects. Therefore, it is 
required to investigate more effective and safer 
therapeutic and natural medicines from traditional 
medicinal plants which offer great potential to work 
as hypoglycaemic agents17. The presence of broad 
arrays of active principles in plants represents diverse 
biological activities that demonstrate insulinomimetic 
activity and anti-diabetic properties. This study 
focused on investigating the potential effect of pure 
compounds like SGSS and Reb-A on alloxan treated 
diabetic rats.  
The higher doses (20 and 30 mg/kg b.wt.) of SGSS 
and Reb-A could produce a significant difference in 
initial and final body weight and the blood glucose 
levels of normal and diabetic rats. After 21 days of 
treatment, the blood glucose levels were found to be 
significantly elevated with reduced body weight in 
diabetic control in comparison to normal control, 
insulin-treated and pure compounds treated 
experimental groups. Oral administration of pure 
compounds to alloxan treated rats produce potent 
in-vivo anti-diabetic or hypoglycaemic effect by 
maintaining blood glucose homeostasis and 
improving body weight without causing any toxic 
effect, unlike other artificial drugs18. This anti-
hyperglycemic effect might be due to the presence of 
different steviol glycosides in the leaves of 
S. rebaudiana which thereby enhance glucose
metabolism by stimulating the efficiency of β-cells of 
islets of Langerhans of the pancreas to produce more 
insulin. These bioactive compounds possess 
antioxidant properties as they scavenge free radicals 
and inhibit cellular oxidative damage and lipid 
peroxidation. According to Saravanan et al.7 oral 
treatment with Reb-A to experimental diabetic rats 
significantly (P <0.05) lower the blood glucose levels 
by decreasing the oxidative stress and protecting the 
integrity of pancreatic β-cells, thus decreasing the 
condition of hyperglycemia. Gregersen et al.19 studied 
the short term supplementation effects of diterpene 
glycoside (stevioside) in a test meal of type 2 diabetic 
patients. It was found that in type 2 diabetic patients, 
stevioside reduces postprandial blood glucose levels 
and exert beneficial effects in metabolizing blood 
glucose by increasing insulin secretion and improving 
diabetes regulation. 
In diabetes, insulin resistance is developed due to 
the production of high levels of reactive oxygen 
species (ROS), which is accompanied by impaired 
antioxidant defence mechanisms causing damage to 
cellular proteins and enzymes along with the increase 
in lipid peroxidation, nitrate concentration, hydroxyl 
radicals, and hyperglycemia20. Malondialdehyde 
content is one of the most common indicators for 
estimating lipid peroxidation, with its increased level 
in erythrocytes alters membrane permeability, 
integrity and functional loss in lipid bilayer membrane 
fluidity. The observation of this study suggests the 
protective effect of SGSS and Reb-A at a dose of 
(20 and 30 mg/kg b.wt.) significantly (P ˂0.05) 
decrease the MDA concentration in plasma of alloxan 
treated diabetic rats when compared with untreated 
diabetic control rats. According to Shivanna et al.21,
administration of Stevia leaves and their extracted 
constituents (polyphenols and fibre) to streptozotocin-
induced diabetic rats reduce the concentration of MDA 
in the liver and improve the status of antioxidant 
enzymes. The main source of oxidative stress and free 
radical generation is glucose oxidation which increases 
the plasma sialic acid content in diabetes. This study 
shows a significant (P ˂0.05) increase in plasma sialic 
acid levels in diabetic rats, administration of SGSS and 
Reb-A (20 and 30 mg/kg b.wt.) to diabetic treated rats 
restore the plasma sialic acid to normal. 
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Cakatay and Kayali22 reported that in diabetic 
animals the total antioxidant capacity (FRAP) levels 
is significantly decreased when compared to non-
diabetic control groups. Similar observations were 
found in this study, where a significant increase in 
plasma (FRAP) of normal control and pure 
compounds treated diabetic rats when compared with 
untreated diabetic rats (Fig. 4). Treatment with SGSS 
and Reb-A (20 and 30 mg/kg) significantly (P ˂0.05) 
enhance the antioxidant potential in treated diabetic 
rats when compared with the untreated diabetic 
control group.  
The biochemical parameters (total cholesterol, 
bilirubin, alkaline phosphatase, urea, creatinine and 
uric acid) indicate that administration with SGSS and 
Reb-A (20 and 30 mg/kg) provide protective effect by 
improving the condition of diabetes mellitus in 
alloxan treated rats and uphold the stable condition in 
normal rats. 
Chronic hyperglycaemia promotes lipid 
peroxidation of low-density lipoprotein (LDL) 
resulting in free radical generation through a 
superoxide-dependent pathway. In diabetes, there is a 
decrease in endogenous insulin release which 
inactivates the production of lipoprotein lipase 
enzymes resulting in hypertriglyceridemia. 
In diabetic dyslipidemia, there are an increased 
concentration in plasma triglyceride and LDL 
cholesterol particles which enhance the free fatty-acid 
release from insulin-resistant fat cells23. However, 
administration of methanolic root extract of 
S. rebaudiana significantly reduces the level of total
cholesterol (TC), triglyceride (TG), low density
lipoprotein (LDL) and very low density lipoprotein
(VLDL) by 53.5, 37.4, 82.3, and 45.6% respectively
when compared with diabetic control group24.
The liver is the largest organ that helps in 
maintaining the concentration of normal blood 
glucose in fasting and postprandial states. Liver 
dysfunction due to insulin resistance leads to 
glycogenolysis (increased production of hepatic 
glucose). Lack of proper storage of triglycerides and 
lipolysis in the liver (insulin-sensitive tissue) elevates 
the hepatic enzyme alkaline phosphatase (ALP) and 
bilirubin in the bloodstream. 
In diabetes, the blood vessels (glomeruli) in the 
kidneys get damaged which affects the glomerular 
filtration rate (GFR) with the decreased synthesis of 
protein and increased tissue proteolysis with raised 
blood urea, creatinine and uric acid levels (Table 2). 
Administration with effective and safe hypoglycemic 
compounds (SGSSand Reb-A) at a dose of (20 and 
30 mg/kg b.wt.) restores all the disturbed parameters 
in alloxan treated rats to the normal level. 
Conclusion 
In conclusion, the results suggest that two reference 
standards steviol glycosides system suitability 
(containing a mixture of nine steviol glycosides) 
and rebaudioside A has significant antioxidative, 
antihyperglycemic and antihyperlipidemic properties. 
These pure compounds in small doses (20 and 
30 mg/kg b.w.) are potentially effective in decreasing 
oxidative damage by enhancing antioxidant levels and 
maintaining glucose homeostasis in diabetic rats. Thus, 
these compounds could be used as a potential drug or 
as a food additive (natural sweetener) in regulating the 
complications of diabetes and improving stress-related 
pathological conditions. Toxicological evaluation 
including clinical trials is required to better understand 
the mechanism of action at the molecular level and to 
settle issues associated with safety concerns. Therefore, 
further studies are necessary to cover a wide spectrum 
of applications of the bioactive compounds (steviol 
glycosides) of the herb S. rebaudiana before 
recommending the patients with type 2 diabetes. 
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Fig. 4 — The total antioxidant activity (FRAP) in normal control
and experimental groups. The values represent the mean±SE for
six rats per group.  
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